Is Smith and Nephew Stock a Good Investment in 2026? SN Fundamentals Explained

Smith & Nephew's board walked away from a transaction that would have roughly doubled the size of the company, and it did so over who would sit in the chief executive's chair rather than over money. The Financial Times reported on Friday 23 October that talks to combine the FTSE 100 group with Johnson & Johnson's DePuy Synthes orthopaedics business had collapsed weeks before a planned mid-October announcement. The structure under discussion valued the J&J unit at as much as $22bn, would have left J&J shareholders owning 50.1% of the combined business, and involved a cash payment to J&J of roughly $10bn funded by new debt. The company's own statement was that it rejected "the proposed appointment of a chief executive, not the deal."

For anyone asking whether Smith and Nephew stock is a good investment, the collapse changes the question rather than answering it: the subject is now unambiguously the standalone business the board chose to keep. What the fundamentals support is a company whose profitability is improving on self-help — first-half trading profit up 8.1% to $566m, a trading margin of 18.3% against 17.7% a year earlier, and a gross margin of 70.9% — while its largest division is barely growing. What would have to go right is orthopaedics itself. Second-quarter Orthopaedics revenue fell 0.2%, full-year sales growth guidance was cut from about 6% to about 4%, and the board's willingness to take on roughly $10bn of debt to buy scale says something precise about how management reads the division's position without it.

What actually happened

The reporting, sourced to the FT and picked up by Reuters and the medical device trade press, describes a deal that was financially agreed and governance-blocked. On price and structure the two sides had converged: up to $22bn for DePuy Synthes, a 50.1% majority of the combined entity for J&J's shareholders, and a roughly $10bn cash payment to J&J that Smith & Nephew would have financed with new borrowings. Several outlets have described the combined business as worth around $34bn, which is a different measure from the $22bn unit valuation and the two should not be used interchangeably.

The breakdown was over leadership. J&J's preferred candidate to run the merged group was Namal Nawana, who heads DePuy Synthes and is a former chief executive of Smith & Nephew. The Smith & Nephew board wanted to retain Deepak Nath, its current chief executive, and the chair, Rupert Soames, treated that as non-negotiable. Reporting indicates J&J was never prepared to proceed on terms where Nath led the combined company. The talks ended several weeks before the matter became public.

Two caveats belong in any assessment of this. Both companies declined to comment, and the account rests on anonymous sourcing — the specific figures are consistently reported across independent write-ups, but they are reported rather than disclosed. Second, J&J has not abandoned the separation: the group has indicated it is leaning towards a spin-off of DePuy Synthes instead, with the separation still targeted for mid-2027. That timetable matters, because a spun-off DePuy Synthes becomes a separately listed orthopaedics competitor rather than a partner.

Against that, the market's response was muted. A report that a transformational $22bn combination had died produced only a modest move in the shares — far smaller than the move a confirmed deal of that size would have caused in either direction. That restraint is itself the most interesting market signal in the story, and it is worth explaining.

Why the market reacted the way it did

There are three reasonable explanations and they are not mutually exclusive. The first is that the talks had already ended weeks earlier, so the news was historical by the time it was published.

The second is that investors never had the transaction in their numbers. Nothing had been announced, no terms had been put to shareholders, and a merger requiring roughly $10bn of new debt against a company of Smith & Nephew's size would have been a substantial leverage event. A shareholder who was unenthusiastic about that structure loses nothing when it disappears. The absence of a sharp fall is consistent with a register that was not pricing the upside.

The third, and the one with the most consequence for the investment case, is that the collapse has no effect on the operating business. The division that would have been transformed is the division that is currently struggling, and it is still struggling on exactly the same terms it was a week ago. Second-quarter Orthopaedics revenue was down 0.2%, with management citing temporary headwinds in US hip implants and continuing challenges in US knees. Nothing about Friday's report changed that, and nothing about it changed the full-year guidance. The shares did not move much because, operationally, nothing moved.

What did change is the information available about how the board sees its own position. A company that turned over $3,097m in the first half was prepared to borrow roughly $10bn and cede majority ownership to acquire scale in orthopaedics. That is not the behaviour of a board that believes its orthopaedics franchise is comfortably competitive at its current size.

The Openbook read

The five factors sort this into something more decision-useful than the headline. Current factor detail is on the SN equity page, and the Openbook screener ranks the medical device peer group on the same measures.

Momentum

Weak, and the collapse does not repair it. The operating momentum signal is the guidance cut: full-year sales growth was reduced from about 6% to about 4% at the half-year stage, with Orthopaedics roughly flat in the second quarter. Against that, Sports Medicine grew 10% year on year, which is a genuinely strong divisional number and the reason the group figure is positive at all. Momentum here is divisional rather than uniform — one franchise is compounding well and the largest one is not, and the blended score reflects the drag more than the bright spot.

Growth

Modest, and flattered by currency. First-half revenue of $3,097m represented underlying growth of 2.3% but reported growth of 4.6%, the difference being about 230 basis points of foreign exchange tailwind. The distinction is load-bearing: at 2.3% underlying the business is growing roughly in line with or slightly behind its end markets, and the reported figure overstates the operating achievement. This is the factor the abandoned merger was intended to fix, and the fix is no longer available on those terms.

Profitability

Clearly improving, and the most creditable part of the recent record. Trading profit rose 8.1% to $566m and the trading profit margin reached 18.3% from 17.7%, driven by a step-up in forecast efficiency savings. Gross margin improved 30 basis points to 70.9%. One important qualification: trading profit is the company's own adjusted measure. On a reported basis, operating profit rose 4.3% to $448m and the operating margin was flat at 14.5%. The gap between an expanding 18.3% adjusted margin and a flat 14.5% reported margin is roughly four percentage points, and an investment case built on the first without acknowledging the second is built on half the evidence. Profitability is improving on the measure management steers to; it has not yet visibly improved on the measure the accounts report.

Solvency

Sound as things stand, and the merger is the best available evidence of headroom. A board does not agree terms requiring roughly $10bn of new debt unless it believes the balance sheet can carry it, and the group has also been running a $500m buyback announced earlier in the year while maintaining its free cash flow and return on invested capital guidance. The merger's collapse leaves the balance sheet unlevered by comparison with what was contemplated — which is a constraint removed rather than an opportunity lost, depending on which way round you read it.

Reward/Risk

Wider than before, in both directions. On the downside, a sub-scale orthopaedics franchise now faces the prospect of a separately listed DePuy Synthes from mid-2027, competing with the focus and the dedicated capital that a spun-off business usually brings, while Smith & Nephew's own knee and hip lines are not growing. On the upside, the episode established that a major industry participant was willing to assign a $22bn value to orthopaedics assets and to pursue a combination at all — which says the strategic interest in consolidating this market is real, and the fact that these talks failed over a personnel question rather than a valuation question leaves that interest intact. The reward/risk read is dispersion, not direction.

The read-across

The clearest read-across is to Johnson & Johnson, where the outcome is a reversion to the spin-off plan rather than a setback to the separation itself. A mid-2027 listing of DePuy Synthes would create a large pure-play orthopaedics company, and the $22bn valuation discussed in these talks is now a publicly reported reference point for what the unit might be worth — useful for J&J shareholders and uncomfortable for competitors, since it sets a benchmark against which other orthopaedics assets will be measured.

For the large US orthopaedics specialists, the signal is that the industry's structure is genuinely in play. Consolidation talks involving two of the four largest participants in hips and knees do not happen in a market where everyone is comfortable with their scale. Pricing pressure in US knee and hip implants, the specific weakness Smith & Nephew's own management identified, is an industry condition rather than a company one, and peers reporting over the coming weeks will be asked about the same lines.

For the FTSE 100, the story is a governance one as much as a sector one. Whether shareholders read the board's refusal as defending strategic continuity or as prioritising incumbency is a judgement for the next annual meeting rather than for this week's share price.

What to watch next

The fixed date in the diary belongs to J&J, not to Smith & Nephew: the DePuy Synthes separation is targeted for mid-2027, and confirmation of the spin-off route — along with any disclosed financials for the unit as it prepares to list — will give the market its first proper look at the asset Smith & Nephew tried to buy. Those numbers will also allow a direct comparison with Smith & Nephew's own orthopaedics performance.

Closer in, the next trading update is where the operating questions get answered. The two to watch are whether US hip implant growth recovers, since management characterised that weakness as temporary and a second soft quarter would undermine that characterisation, and whether the roughly 4% full-year sales growth guidance holds after being cut from about 6%. The trading profit margin trajectory matters equally: the improvement to 18.3% was attributed to efficiency savings, so the question is whether that programme continues to deliver when revenue growth is only 2.3% underlying, and whether any of it starts to show up in the reported operating margin that has so far stayed flat at 14.5%.

Finally, there is the possibility that nothing is settled. The talks failed over a single appointment, not over price or strategic logic, and both the asset and the rationale still exist. A revived approach in some form — before or after a mid-2027 listing — cannot be ruled out, and it is the single event that would most change the reward/risk picture described above.